The Sputnik combination has so far given better results with Astrazeneca than with Sinopharm

The first results of the survey on vaccine combination in the city of Buenos Aires have so far shown that the option Sputnik V – Astrazeneca is more efficient than Sputnik V – Sinopharm, according to an advance he was able to access Bugle.

These are preliminary results and sources from the Buenos Aires Ministry of Health do not rule out that Sinopharm can also be used as a second dose before the Russian disappeared. To have more results, you will have to wait a few days.

The study carried out by the Ministry of Health of Buenos Aires would show that in the combination of platforms, the one that offers the most effect is that of Astrazeneca with Sputnik, according to health sources told in Clarín. The advantage is the potential of both vaccines to generate a higher percentage of immune system cells. On the other hand, Sinopharm’s did not bring much benefit in terms of union with the Gamaleya Institute.

However, some specialists expect the the best result of the combination with Sputnik will be with a messenger RNA vaccine (Pfizer or Moderna).

“From the readings I have been able to do so far and also consulted the Argentine Society of Infectology, we can say that the combination of Sputnik, a viral vector, with Moderna, whose platform is the Messenger RNA, is the best combination. The one that would increase the percentage of immunological coverage the most ”, he declared. Bugle Carlos Di Pietrantonio, epidemiologist, Master in public health.

As he could know Bugle, the final results of the City’s study with the Moderna vaccine combination will be available within one to two weeks. The prediction is that Moderna could provide greater amplification of the immune response.

The trial, which began with 180 volunteers on July 7, gave encouraging results and went optimally in terms of safety parameters. According to sources who collaborated in the immunological determinations and in the absence of the second dose of Sputnik V, andIn two weeks this heterologous combination could be opened to the entire population in order to complete the two-dose schedule. But, it will be the nation’s health authority that will make the decision.

Only in the capital there are 741,323 people vaccinated with component 1 of the Russian vaccine. Of these, 197,778 completed the two-dose schedule, so 543,545 are awaiting the assignment of a new shift. Of these, some 150,000 have already met the 12-week deadline set out in the strategy for applying a dose to the greatest number of people.

But this methodology has changed and it has been fixed speed up vaccination with second doses to add protection against the threat of the Delta variant. Nationally, the number reaches nearly 7 million people who have received one dose and are waiting for the second.

In view of the lack of component 2 of Sputnik V, the Province of Buenos Aires also carried out a safety study on the combinations of Sputnik V vaccines with Sinopharm and with Astrazeneca. The tests did not pay off no serious adverse events.

MG